KRAS and cancer: Unfortunately, FTIs failed in clinical trials showing no efficacy against NRAS and KRAS-driven cancers (Smalley and Eisen, 2003; Konstantinopoulos et al., 2007; Niessner et al., 2011; Gajewski et al., 2012; Margolin et al., 2012; Cox et al., 2015).